You are totally obsessed with revenue and I just don't get why. This is not CSL or PME with multiple products in the market or multiple deals in place - it is effectively still an early-stage biotech with the good fortune of having a share of a commercialised asset that brings in enough money to fund the development of it's pipeline.
If we had commercialised 2591 and revenue was just not materialising then I would be worried and would absolutely share your view - but we don't.
You bang on and on about revenue and drops in earnings - nobody really cares and nobody really expects anything different at this stage. If you think differently and think revenue is the only thing that matters then you have not done your DD and/or have invested too early in the company.
I would confidently say that most people are here for 2591 and they know that revenue will likely fluctuate - we don't need you to point out the obvious every 5 mins.
I would tell you to put a lid on it and/or to give it a rest but many have tried and you continue. Moreover, I don't think your intentions for posting as you do are genuine, so it would make little difference. Spreading fear and negativity for your own personal financial gain is low in my opinion.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)